

John R Hurst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5863575/publications.pdf>

Version: 2024-02-01

235
papers

15,548
citations

30070

54
h-index

19190

118
g-index

256
all docs

256
docs citations

256
times ranked

13957
citing authors

#	ARTICLE	IF	CITATIONS
1	Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2010, 363, 1128-1138.	27.0	2,359
2	“Long-COVID”: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. <i>Thorax</i> , 2021, 76, 396-398.	5.6	636
3	Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2020, 15, e0233147.	2.5	605
4	Early Therapy Improves Outcomes of Exacerbations of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 1298-1303.	5.6	596
5	Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2177.	7.4	443
6	Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017, 49, 1600791.	6.7	438
7	Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD. <i>Chest</i> , 2005, 128, 1995-2004.	0.8	404
8	Increased Risk of Myocardial Infarction and Stroke Following Exacerbation of COPD. <i>Chest</i> , 2010, 137, 1091-1097.	0.8	398
9	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1275-1287.	10.7	394
10	Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. <i>European Respiratory Journal</i> , 2016, 47, 186-193.	6.7	393
11	Use of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 867-874.	5.6	391
12	Long-term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive Pulmonary Disease Exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 1139-1147.	5.6	384
13	Systemic and Upper and Lower Airway Inflammation at Exacerbation of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 71-78.	5.6	304
14	British Thoracic Society Guideline for bronchiectasis in adults. <i>Thorax</i> , 2019, 74, 1-69.	5.6	291
15	Effect of Interactions Between Lower Airway Bacterial and Rhinoviral Infection in Exacerbations of COPD. <i>Chest</i> , 2006, 129, 317-324.	0.8	288
16	Hospitalized Exacerbations of COPD. <i>Chest</i> , 2015, 147, 999-1007.	0.8	269
17	Exacerbations and Time Spent Outdoors in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 446-452.	5.6	267
18	Temporal Clustering of Exacerbations in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 369-374.	5.6	231

#	ARTICLE	IF	CITATIONS
19	Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). <i>BMJ Open</i> , 2014, 4, e005540-e005540.	1.9	203
20	Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 329-339.	5.6	196
21	Cardiovascular disease and COPD: dangerous liaisons?. <i>European Respiratory Review</i> , 2018, 27, 180057.	7.1	187
22	Improving lung health in low-income and middle-income countries: from challenges to solutions. <i>Lancet, The</i> , 2021, 397, 928-940.	13.7	176
23	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, e4-e27.	5.6	166
24	Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to Evaluate Severity of COPD Exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1218-1224.	5.6	164
25	Exacerbation rate, health status and mortality in COPD – a review of potential interventions. <i>International Journal of COPD</i> , 2009, 4, 203.	2.3	156
26	Time course and pattern of COPD exacerbation onset. <i>Thorax</i> , 2012, 67, 238-243.	5.6	139
27	COPDâbronchiectasis overlap syndrome. <i>European Respiratory Journal</i> , 2015, 45, 310-313.	6.7	139
28	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015, 45, 879-905.	6.7	138
29	British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> . 2017, 5, 938-945.	3.8	138
30	The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. <i>European Respiratory Journal</i> , 2018, 52, 1800328.	6.7	138
31	Cardiovascular Risk, Myocardial Injury, and Exacerbations of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1091-1099.	5.6	134
32	Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017, 50, 1602265.	6.7	131
33	Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 647-662.	2.5	128
34	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1251-1258.	5.6	121
35	Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records. <i>PLoS ONE</i> , 2016, 11, e0151357.	2.5	117
36	Lung consequences in adults born prematurely. <i>Thorax</i> , 2015, 70, 574-580.	5.6	109

#	ARTICLE	IF	CITATIONS
37	Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2009, 103, 216-223.	2.9	107
38	Serum IP-10 as a Biomarker of Human Rhinovirus Infection at Exacerbation of COPD. <i>Chest</i> , 2010, 137, 812-822.	0.8	101
39	Relationships Among Bacteria, Upper Airway, Lower Airway, and Systemic Inflammation in COPD. <i>Chest</i> , 2005, 127, 1219.	0.8	101
40	Lung disease in primary antibody deficiency. <i>Lancet Respiratory Medicine</i> , 2015, 3, 651-660.	10.7	92
41	Reduction in hospitalised COPD exacerbations during COVID-19: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0255659.	2.5	90
42	The Impact of Ischemic Heart Disease on Symptoms, Health Status, and Exacerbations in Patients With COPD. <i>Chest</i> , 2012, 141, 851-857.	0.8	89
43	Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis. <i>European Respiratory Review</i> , 2020, 29, 190166.	7.1	87
44	The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1467-1478.	10.7	84
45	Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. <i>BMC Pulmonary Medicine</i> , 2010, 10, 52.	2.0	78
46	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Review</i> , 2015, 24, 159-172.	7.1	72
47	How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 139-149.	5.6	68
48	Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. <i>European Journal of Internal Medicine</i> , 2020, 73, 1-6.	2.2	67
49	Respiratory and Cardiovascular Outcomes in Survivors of Extremely Preterm Birth at 19 Years. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 422-432.	5.6	67
50	Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD). <i>Respiratory Medicine</i> , 2004, 98, 767-770.	2.9	66
51	Update on alpha-1 antitrypsin deficiency: New therapies. <i>Journal of Hepatology</i> , 2016, 65, 413-424.	3.7	66
52	Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. <i>Clinical Epidemiology</i> , 2016, Volume 8, 771-782.	3.0	65
53	The high mental health burden of "Long COVID" and its association with on-going physical and respiratory symptoms in all adults discharged from hospital. <i>European Respiratory Journal</i> , 2021, 57, 2004364.	6.7	62
54	Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. <i>Thorax</i> , 2015, 70, 930-938.	5.6	61

#	ARTICLE	IF	CITATIONS
55	Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study. <i>Respiratory Research</i> , 2015, 16, 16.	3.6	60
56	Bronchiectasis and the risk of cardiovascular disease: a population-based study. <i>Thorax</i> , 2017, 72, 161-166.	5.6	60
57	Factors associated with change in exacerbation frequency in COPD. <i>Respiratory Research</i> , 2013, 14, 79.	3.6	58
58	The heterogeneity of systemic inflammation in bronchiectasis. <i>Respiratory Medicine</i> , 2017, 127, 33-39.	2.9	58
59	Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 294-302.	5.6	56
60	Monitoring of Physiological Parameters to Predict Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review. <i>Journal of Clinical Medicine</i> , 2016, 5, 108.	2.4	54
61	25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2012, 12, 28.	2.0	47
62	Respiratory Infections and Antibiotic Usage in Common Variable Immunodeficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 159-168.e3.	3.8	46
63	The challenges of deploying artificial intelligence models in a rapidly evolving pandemic. <i>Nature Machine Intelligence</i> , 2020, 2, 298-300.	16.0	45
64	Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. <i>BMC Medicine</i> , 2009, 7, 40.	5.5	44
65	Global Alliance for Chronic Disease researchers' statement on multimorbidity. <i>The Lancet Global Health</i> , 2018, 6, e1270-e1271.	6.3	43
66	Are early life factors considered when managing respiratory disease? A British Thoracic Society survey of current practice: Table A1. <i>Thorax</i> , 2012, 67, 1110-1110.	5.6	42
67	COPD Exacerbations. <i>Immunology and Allergy Clinics of North America</i> , 2013, 33, 95-115.	1.9	42
68	Gaps in COPD Guidelines of Low- and Middle-Income Countries. <i>Chest</i> , 2021, 159, 575-584.	0.8	41
69	Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2015, 109, 1147-1154.	2.9	40
70	Risk factors and associated outcomes of hospital readmission in COPD: A systematic review. <i>Respiratory Medicine</i> , 2020, 173, 105988.	2.9	40
71	Specialty COPD care during COVID-19: patient and clinician perspectives on remote delivery. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000817.	3.0	37
72	COPD Exacerbations. <i>Medical Clinics of North America</i> , 2012, 96, 789-809.	2.5	35

#	ARTICLE	IF	CITATIONS
73	Activity, Severity and Impact of Respiratory Disease in Primary Antibody Deficiency Syndromes. <i>Journal of Clinical Immunology</i> , 2014, 34, 68-75.	3.8	34
74	Building toolkits for COPD exacerbations: lessons from the past and present. <i>Thorax</i> , 2019, 74, 898-905.	5.6	34
75	Exacerbation Phenotyping in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 625-626.	5.6	33
76	Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group. <i>Journal of Clinical Immunology</i> , 2019, 39, 45-54.	3.8	32
77	Nasal symptoms, airway obstruction and disease severity in chronic obstructive pulmonary disease. <i>Clinical Physiology and Functional Imaging</i> , 2006, 26, 251-256.	1.2	31
78	The Biology of a Chronic Obstructive Pulmonary Disease Exacerbation. <i>Clinics in Chest Medicine</i> , 2007, 28, 525-536.	2.1	31
79	Deficiency Mutations of Alpha-1 Antitrypsin. Effects on Folding, Function, and Polymerization. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 54, 71-80.	2.9	31
80	Discriminative Accuracy of Chronic Obstructive Pulmonary Disease Screening Instruments in 3 Low- and Middle-Income Country Settings. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 151.	7.4	31
81	British Thoracic Society survey of rehabilitation to support recovery of the post-COVID-19 population. <i>BMJ Open</i> , 2020, 10, e040213.	1.9	29
82	Pulmonary Lobe Segmentation With Probabilistic Segmentation of the Fissures and a Groupwise Fissure Prior. <i>IEEE Transactions on Medical Imaging</i> , 2017, 36, 1650-1663.	8.9	28
83	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. <i>Gut</i> , 2022, 71, 415-423.	12.1	28
84	Research priorities for exacerbations of COPD. <i>Lancet Respiratory Medicine</i> , 2021, 9, 824-826.	10.7	28
85	Challenges in the Implementation of Chronic Obstructive Pulmonary Disease Guidelines in Low- and Middle-Income Countries: An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1269-1277.	3.2	27
86	Effectiveness-implementation of COPD case finding and self-management action plans in low- and middle-income countries: global excellence in COPD outcomes (GECO) study protocol. <i>Trials</i> , 2018, 19, 571.	1.6	26
87	A Systematic Literature Review of the Humanistic Burden of COPD. <i>International Journal of COPD</i> , 2021, Volume 16, 1303-1314.	2.3	26
88	Critical review of multimorbidity outcome measures suitable for low-income and middle-income country settings: perspectives from the Global Alliance for Chronic Diseases (GACD) researchers. <i>BMJ Open</i> , 2020, 10, e037079.	1.9	25
89	A clinical review of long-COVID with a focus on the respiratory system. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 174-179.	2.6	25
90	Detrended fluctuation analysis of peak expiratory flow and exacerbation frequency in COPD. <i>European Respiratory Journal</i> , 2012, 40, 1123-1129.	6.7	24

#	ARTICLE	IF	CITATIONS
91	Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 606099.	4.8	24
92	Correlates and assessment of excess cardiovascular risk in bronchiectasis. <i>European Respiratory Journal</i> , 2017, 50, 1701127.	6.7	23
93	Differences in systemic adaptive immunity contribute to the "frequent exacerbator" COPD phenotype. <i>Respiratory Research</i> , 2016, 17, 140.	3.6	22
94	Nutritional supplementation during pulmonary rehabilitation in COPD: A systematic review. <i>Chronic Respiratory Disease</i> , 2020, 17, 147997312090495.	2.4	22
95	Predictors of 30- and 90-Day COPD Exacerbation Readmission: A Prospective Cohort Study. <i>International Journal of COPD</i> , 2021, Volume 16, 2769-2781.	2.3	22
96	Structural and Functional Co-conspirators in Chronic Obstructive Pulmonary Disease Exacerbations. <i>Proceedings of the American Thoracic Society</i> , 2007, 4, 602-605.	3.5	21
97	The Potential Value of Biomarkers in Diagnosis and Staging of COPD and Exacerbations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 267-275.	2.1	21
98	Susceptibility to exacerbation in COPD. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, e29.	10.7	21
99	Airway microbiome in adult survivors of extremely preterm birth: the EPICure study. <i>European Respiratory Journal</i> , 2019, 53, 1801225.	6.7	20
100	Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. <i>International Journal of COPD</i> , 2018, Volume 13, 781-792.	2.3	19
101	ROSE: radiology, obstruction, symptoms and exposure " a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. <i>ERJ Open Research</i> , 2021, 7, 00399-2021.	2.6	19
102	Use and utility of a 24-hour Telephone Support Service for "high risk" patients with COPD. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2010, 19, 260-265.	2.3	18
103	Size at birth, growth trajectory in early life, and cardiovascular and metabolic risks in early adulthood: EPICure study. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2021, 106, 149-155.	2.8	18
104	Urban-Rural Disparities in Chronic Obstructive Pulmonary Disease Management and Access in Uganda. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 17-28.	0.7	18
105	Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade. <i>Journal of Global Health</i> , 2021, 11, 15003.	2.7	18
106	Once Daily Versus Overnight and Symptom Versus Physiological Monitoring to Detect Exacerbations of Chronic Obstructive Pulmonary Disease: Pilot Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2020, 8, e17597.	3.7	18
107	Republished: Lung consequences in adults born prematurely. <i>Postgraduate Medical Journal</i> , 2015, 91, 712-718.	1.8	17
108	Strategies for the prevention, diagnosis and treatment of COPD in low- and middle- income countries: the importance of primary care. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1563-1577.	2.5	17

#	ARTICLE	IF	CITATIONS
109	Dose response of continuous positive airway pressure on nasal symptoms, obstruction and inflammation<i>in vivo</i>and<i>in vitro</i>. European Respiratory Journal, 2012, 40, 1180-1190.	6.7	16
110	A Patient Charter for Chronic Obstructive Pulmonary Disease. Advances in Therapy, 2021, 38, 11-23.	2.9	16
111	The use of whole-exome sequencing to disentangle complex phenotypes. European Journal of Human Genetics, 2016, 24, 298-301.	2.8	15
112	<p>Global use, utility, and methods of tele-health in COPD: a health care provider survey</p>. International Journal of COPD, 2019, Volume 14, 1713-1719.	2.3	15
113	Use, utility and methods of telehealth for patients with COPD in England and Wales: a healthcare provider survey. BMJ Open Respiratory Research, 2019, 6, e000345.	3.0	15
114	National clinical audit for hospitalised exacerbations of COPD. ERJ Open Research, 2020, 6, 00208-2020.	2.6	15
115	Caring for patients with COPD and COVID-19: a viewpoint to spark discussion. Thorax, 2020, 75, 1035-1039.	5.6	15
116	How to assess the severity of bronchiectasis. European Respiratory Journal, 2014, 43, 1217-1219.	6.7	14
117	Development, deployment and evaluation of digitally enabled, remote, supported rehabilitation for people with long COVID-19 (Living With COVID-19 Recovery): protocol for a mixed-methods study. BMJ Open, 2022, 12, e057408.	1.9	14
118	Cardiovascular outcomes in patients with COPD-OSA overlap syndrome: A systematic review and meta-analysis. Sleep Medicine Reviews, 2022, 63, 101627.	8.5	13
119	Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 307, L311-L316.	2.9	12
120	<p>A Novel Case-Finding Instrument for Chronic Obstructive Pulmonary Disease in Low- and Middle-Income Country Settings</p>. International Journal of COPD, 2020, Volume 15, 2769-2777.	2.3	12
121	Pulmonary rehabilitation for COPD: A narrative review and call for further implementation in Saudi Arabia. Annals of Thoracic Medicine, 2021, 16, 299.	1.8	12
122	Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review. ERJ Open Research, 2021, 7, 00441-2021.	2.6	12
123	Chronic Obstructive Pulmonary Disease as a Risk Factor for Cardiovascular Disease. A View from the SUMMIT. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 2-4.	5.6	11
124	Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians. BMJ Open Respiratory Research, 2021, 8, e001088.	3.0	11
125	Mechanism of Statin-Associated Mortality Reduction in COPD. Chest, 2007, 132, 1409.	0.8	10
126	Validation of the Saint Georgeâ€™s Respiratory Questionnaire in Uganda. BMJ Open Respiratory Research, 2018, 5, e000276.	3.0	10

#	ARTICLE	IF	CITATIONS
127	Pulmonary rehabilitation, physical activity and aortic stiffness in COPD. <i>Respiratory Research</i> , 2019, 20, 166.	3.6	10
128	Managing Granulomatous Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. <i>Frontiers in Immunology</i> , 2020, 11, 606333.	4.8	10
129	COPD exacerbation phenotypes in a real-world five year hospitalisation cohort. <i>Respiratory Medicine</i> , 2020, 167, 105979.	2.9	10
130	Interstitial lung disease in primary immunodeficiency: towards a brighter future. <i>European Respiratory Journal</i> , 2020, 55, 2000089.	6.7	10
131	Remote Assessment of Lung Disease and Impact on Physical and Mental Health (RALPMH): Protocol for a Prospective Observational Study. <i>JMIR Research Protocols</i> , 2021, 10, e28873.	1.0	10
132	Predictive modeling of COPD exacerbation rates using baseline risk factors. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211073.	2.6	10
133	SERPINA1 11478G->A variant, serum α 1-antitrypsin, exacerbation frequency and FEV1 decline in COPD. <i>Thorax</i> , 2011, 66, 418-424.	5.6	9
134	Microbial dysbiosis in bronchiectasis. <i>Lancet Respiratory Medicine</i> , 2014, 2, 945-947.	10.7	9
135	CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. <i>International Journal of COPD</i> , 2021, Volume 16, 2301-2322.	2.3	9
136	COVID-19 and α 1-antitrypsin exacerbation frequency in COPD. <i>Thorax</i> , 2021, 76, 432-433.	5.6	9
137	Acceptability of hygiene, face covering and social distancing interventions to prevent exacerbations in people living with airways diseases. <i>Thorax</i> , 2022, 77, 505-507.	5.6	9
138	Application of oxygen saturation variability analysis for the detection of exacerbation in individuals with COPD: A proof-of-concept study. <i>Physiological Reports</i> , 2021, 9, e15132.	1.7	9
139	Consolidation and Exacerbation of COPD. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 44.	2.9	8
140	Pneumonia in exacerbations of COPD: what is the clinical significance?. <i>ERJ Open Research</i> , 2020, 6, 00282-2019.	2.6	8
141	Multimorbidity: Not Just for the West. <i>Global Heart</i> , 2020, 15, 45.	2.3	8
142	Nasal and systemic inflammation in Chronic Obstructive Pulmonary Disease (COPD). <i>Respiratory Medicine</i> , 2022, 195, 106774.	2.9	8
143	Precision Medicine in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 593-594.	5.6	7
144	Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons. <i>International Journal of COPD</i> , 2020, Volume 15, 1529-1543.	2.3	7

#	ARTICLE	IF	CITATIONS
145	Outcome measures in a combined exercise rehabilitation programme for adults with COPD and chronic heart failure: A preliminary stakeholder consensus event. <i>Chronic Respiratory Disease</i> , 2019, 16, 147997311986795.	2.4	6
146	COPD Exacerbations: A Patient and Physician's Perspective. <i>Advances in Therapy</i> , 2020, 37, 10-16.	2.9	6
147	The effect of HIV status on the frequency and severity of acute respiratory illness. <i>PLoS ONE</i> , 2020, 15, e0232977.	2.5	6
148	A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study. <i>ERJ Open Research</i> , 2021, 7, 00077-2021.	2.6	6
149	Granulomatous lymphocytic interstitial lung disease: an international research prioritisation. <i>ERJ Open Research</i> , 2021, 7, 00467-2021.	2.6	6
150	Development of a core outcome set for multimorbidity trials in low/middle-income countries (COSMOS): study protocol. <i>BMJ Open</i> , 2022, 12, e051810.	1.9	6
151	The rhythm of chronic obstructive pulmonary disease exacerbations. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 1285-1286.	5.0	5
152	Role of a functional polymorphism in the F2R gene promoter in sarcoidosis. <i>Respirology</i> , 2015, 20, 1285-1287.	2.3	5
153	<p>Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1751-1787.	2.3	5
154	Illness representations of chronic obstructive pulmonary disease (COPD) to inform health education strategies and research design learning from rural Uganda. <i>Health Education Research</i> , 2020, 35, 258-269.	1.9	5
155	Operational Modeling with Health Economics to Support Decision Making for COPD Patients. <i>Health Services Research</i> , 2021, 56, 1271-1280.	2.0	5
156	Upper airway symptoms associate with the eosinophilic phenotype of COPD. <i>ERJ Open Research</i> , 2021, 7, 00184-2021.	2.6	5
157	Does pay-for-performance improve patient outcomes in acute exacerbation of COPD admissions?. <i>Thorax</i> , 2022, 77, 239-246.	5.6	5
158	Non-invasive testing for liver pathology in alpha-1 antitrypsin deficiency. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000820.	3.0	5
159	Predictive Factors for and Complications of Bronchiectasis in Common Variable Immunodeficiency Disorders. <i>Journal of Clinical Immunology</i> , 2022, 42, 572-581.	3.8	5
160	Quality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective. <i>Advances in Therapy</i> , 2022, 39, 2302-2322.	2.9	5
161	Intersession repeatability of a novel nasal lavage technique. <i>Translational Research</i> , 2011, 158, 163-168.	5.0	4
162	Effect of time and day of admission on hospital care quality for patients with chronic obstructive pulmonary disease exacerbation in England and Wales: single cohort study. <i>BMJ Open</i> , 2017, 7, e015532.	1.9	4

#	ARTICLE	IF	CITATIONS
163	Pulmonary rehabilitation and cardiovascular risk in COPD: a systematic review. COPD Research and Practice, 2017, 3, .	0.7	4
164	Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?. European Respiratory Journal, 2018, 51, 1702577.	6.7	4
165	Enrichment of the airway microbiome in people living with HIV with potential pathogenic bacteria despite antiretroviral therapy. EClinicalMedicine, 2020, 24, 100427.	7.1	4
166	BronchUK: protocol for an observational cohort study and biobank in bronchiectasis. ERJ Open Research, 2021, 7, 00775-2020.	2.6	4
167	Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. Trials, 2021, 22, 213.	1.6	4
168	Global Burden of COPD. , 2020, , 1-20.		4
169	Tapering analysis of airways with bronchiectasis. , 2018, , .		4
170	Upper airway symptoms and Small Airways Disease in Chronic Obstructive Pulmonary Disease, COPD. Respiratory Medicine, 2022, 191, 106710.	2.9	4
171	“NEWS2” as an Objective Assessment of Hospitalised COPD Exacerbation Severity. International Journal of COPD, 2022, Volume 17, 763-772.	2.3	4
172	Phenotype-based Care in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 935-936.	5.6	3
173	COPD exacerbations: transforming outcomes through research. Lancet Respiratory Medicine, the, 2018, 6, 172-174.	10.7	3
174	<p>Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study</p>. Journal of Pragmatic and Observational Research, 2020, Volume 11, 55-66.	1.5	3
175	Relationship of CT densitometry to lung physiological parameters and health status in alpha-1 antitrypsin deficiency: initial report of a centralised database of the NIHR rare diseases translational research collaborative. BMJ Open, 2020, 10, e036045.	1.9	3
176	Risk for development of active tuberculosis in patients with chronic airway disease” a systematic review of evidence. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 390-398.	1.8	3
177	Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals. International Journal of COPD, 2021, Volume 16, 3009-3016.	2.3	3
178	The National COPD Audit “ what you need to know. Clinical Medicine, 2019, 19, 499-502.	1.9	3
179	CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients. Patient Related Outcome Measures, 0, Volume 13, 53-68.	1.2	3
180	Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis. Annals of the American Thoracic Society, 2022, 19, 1489-1497.	3.2	3

#	ARTICLE	IF	CITATIONS
181	Dyspnoea perception and susceptibility to exacerbation in COPD. <i>Thorax</i> , 2017, 72, 107-108.	5.6	2
182	Development and Validity Assessment of a Chronic Obstructive Pulmonary Disease Knowledge Questionnaire in Low- and Middle-Income Countries. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1298-1305.	3.2	2
183	The Impact of Re-Admissions in COPD. <i>Archivos De Bronconeumologia</i> , 2021, 58, 109-110.	0.8	2
184	Editorial: Interstitial Lung Disease in Primary Immunodeficiencies. <i>Frontiers in Immunology</i> , 2021, 12, 699126.	4.8	2
185	Multi-scale Analysis of Imaging Features and Its Use in the Study of COPD Exacerbation Susceptible Phenotypes. <i>Lecture Notes in Computer Science</i> , 2014, 17, 417-424.	1.3	2
186	The clinical utility of forced oscillation technique during hospitalisation in patients with exacerbation of COPD. <i>ERJ Open Research</i> , 2021, 7, 00448-2021.	2.6	2
187	The extremely preterm young adult – State of the art. <i>Seminars in Fetal and Neonatal Medicine</i> , 2022, 27, 101365.	2.3	2
188	An introduction to conducting COPD exacerbation research. <i>Respiratory Medicine: COPD Update</i> , 2009, 5, 38-44.	0.0	1
189	Temporal Clustering of Exacerbations in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 985-985.	5.6	1
190	Chronic obstructive pulmonary disease: aetiology, pathology, physiology and outcome. <i>Medicine</i> , 2012, 40, 257-261.	0.4	1
191	Neither anti-inflammatory nor antibiotic treatment significantly shortens duration of cough in acute bronchitis compared with placebo. <i>Evidence-Based Medicine</i> , 2014, 19, 98-98.	0.6	1
192	Multi-level Multi-task Structured Sparse Learning for Diagnosis of Schizophrenia Disease. <i>Lecture Notes in Computer Science</i> , 2017, 10435, 46-54.	1.3	1
193	What is a COPD-Like Spirometry Test Result in Resource Constrained Settings?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 213-214.	1.6	1
194	Reply to Lan and Shi: Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 390-392.	5.6	1
195	Gastroesophageal Reflux Disease (GERD) and COPD. , 2018, , 165-174.		1
196	Gastro-oesophageal reflux disease and COPD. , 2013, , 105-116.		1
197	Disease progression patterns in COPD. , 2018, , .		1
198	Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
199	Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD). , 2019, , .		1
200	Patient pathway modelling using Discrete Event Simulation to reduce readmissions in COPD. , 2019, , .		1
201	Reproducibility of an airway tapering measurement in computed tomography with application to bronchiectasis. Journal of Medical Imaging, 2019, 6, 1.	1.5	1
202	Patient pathway modelling using discrete event simulation to improve the management of COPD. Journal of the Operational Research Society, 0, , 1-25.	3.4	1
203	The nose and sinuses in COPD. , 0, , 138-147.		1
204	Cost-Accuracy Analysis of Chronic Obstructive Pulmonary Disease Screening in Low- and Middle-Income Countries. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 353-356.	5.6	1
205	Early Therapy in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 292-292.	5.6	0
206	Changes to letters in Thorax. Thorax, 2007, 62, 474-474.	5.6	0
207	“Temporal Clustering” of COPD Exacerbations May Reflect Corticosteroid Withdrawal. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 483-483.	5.6	0
208	Frequent Exacerbators in COPD: Who Are They?. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 284-284.	5.6	0
209	Management of Exacerbations in Chronic Obstructive Pulmonary Disease. , 2012, , 562-567.		0
210	Chronic obstructive pulmonary disease: aetiology, pathology, physiology and outcome. Medicine, 2016, 44, 305-309.	0.4	0
211	One-off Spirometry Is Insufficient to Rule In or Rule Out Mild to Moderate Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 254-256.	5.6	0
212	<p>A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD</p>. International Journal of COPD, 2020, Volume 15, 3093-3103.	2.3	0
213	New developments in respiratory medicine: a primary immunodeficiency perspective. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 549-556.	2.3	0
214	Correction to: “We can’t carry the weight of the whole world” Illness experiences among Peruvian older adults with symptoms of depression and anxiety. International Journal of Mental Health Systems, 2020, 14, .	2.7	0
215	Chronic obstructive pulmonary disease: aetiology, pathology, physiology and outcome. Medicine, 2020, 48, 328-332.	0.4	0
216	Addressing a system failure to diagnose COPD and asthma. Lancet Respiratory Medicine,the, 2021, 9, 814-816.	10.7	0

#	ARTICLE	IF	CITATIONS
217	Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. , 2008, , 517-521.		0
218	Airway tapering in bronchiectatic and healthy airways. , 2018, , .		0
219	Late Breaking Abstract - Characteristics and treatment of patients with comorbid COPD and heart failure. , 2018, , .		0
220	Impact of Physical Frailty on Pulmonary Rehabilitation and Hospitalisation in COPD. , 2018, , .		0
221	Cardiovascular risk and exercise capacity in COPD. , 2018, , .		0
222	A randomised crossover trial investigating the effect of a portable positive pressure ventilation device on exercise tolerance in patients with COPD. , 2018, , .		0
223	Investigation of shortened lung clearance index (LCI) in the Bronch-UK Clinimetrics study.. , 2018, , .		0
224	COPD and emphysema. , 2019, , 324-331.		0
225	Late Breaking Abstract - Arterial Stiffness and Cardiovascular Risk in hospitalised COPD patients. , 2019, , .		0
226	Nutritional Supplementation during Pulmonary Rehabilitation in Stable Chronic Obstructive Pulmonary Disease: A Systematic Review. , 2019, , .		0
227	Evidence-implementation gaps in low- and middle-income countries' COPD guidelines. , 2020, , .		0
228	COPD: definition, severity and impact of pulmonary exacerbations. , 0, , 13-24.		0
229	Primary immunodeficiency. , 0, , 153-166.		0
230	Predictive modelling of COPD exacerbation rates using baseline risk factors. , 2020, , .		0
231	Upper Respiratory Symptoms in Patients with Chronic Obstructive Pulmonary Disease. , 2020, , .		0
232	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0
233	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0
234	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0

#	ARTICLE	IF	CITATIONS
235	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0